What is the recommended management for central sleep apnea?

Management of Central Sleep Apnea

The recommended first-line management for central sleep apnea depends critically on the underlying etiology, with positive airway pressure therapy (CPAP initially, then ASV if needed), acetazolamide, and optimization of underlying conditions forming the cornerstone of treatment, while adaptive servo-ventilation use in heart failure requires careful patient selection based on ejection fraction. 1

Initial Approach: Treat the Underlying Cause First

Before initiating specific CSA therapies, aggressively optimize any underlying medical conditions:

• Heart failure: Maximize guideline-directed medical therapy
• Opioid-induced CSA: Reduce or discontinue opioids when feasible
• High altitude: Consider descent if symptoms are severe
• Treatment-emergent CSA: May resolve spontaneously; observe for 3 months before treating

This foundational step is critical because CSA often improves or resolves with proper management of the precipitating condition 1.

Stepwise Treatment Algorithm

Step 1: Trial of CPAP Therapy

Start with continuous positive airway pressure (CPAP) as the initial PAP modality for most CSA patients, regardless of etiology 2. CPAP is:

• Less expensive and more widely available than ASV
• Effective for many patients, particularly those with mixed obstructive/central events
• The required first step before escalating to ASV in most guidelines

Key caveat: CPAP may worsen CSA in some patients or prove ineffective for predominantly central events.

Step 2: Pharmacological Therapy - Acetazolamide

The AASM suggests using oral acetazolamide for CSA across multiple etiologies 1:

• Primary CSA
• CSA due to heart failure
• Medication/substance-induced CSA
• Treatment-emergent CSA
• CSA due to medical conditions
• High-altitude CSA

This is a conditional recommendation with low certainty evidence, but acetazolamide represents a reasonable pharmacological option, particularly when PAP therapy fails or is not tolerated.

Step 3: Adaptive Servo-Ventilation (ASV) - With Critical Restrictions

ASV is highly effective at suppressing central events and improving quality of life 2, BUT its use requires careful patient stratification based on heart failure status:

Safe ASV Use:

• CSA WITHOUT heart failure (primary CSA, treatment-emergent CSA, opioid-induced CSA): ASV is appropriate after CPAP failure 2
• Heart failure with PRESERVED ejection fraction (LVEF >45%): ASV can be used after CPAP trial fails 2
• Heart failure with LVEF 30-45%: ASV may be used in experienced centers with close monitoring after CPAP failure 2

Restricted ASV Use:

• Heart failure with severely reduced ejection fraction (LVEF <30%): ASV should be limited to experienced centers with close monitoring 1. The European guidelines note this group has mortality comparable to advanced lung cancer and sometimes consider ASV only in palliative care settings for highly symptomatic patients 2

Critical distinction: The 2025 AASM and European guidelines represent a significant evolution from the 2015 SERVE-HF study concerns. The more recent ADVENT-HF trial (2025) showed no harm signal with modern ASV devices and settings, though it was underpowered for definitive safety conclusions 2. Current ASV devices use different algorithms than those in SERVE-HF (no fixed minimum pressure support, auto-adjusting EPAP) 2.

Step 4: Supplemental Oxygen

The AASM suggests low-flow oxygen for:

• CSA due to heart failure (conditional recommendation, low certainty) 1
• CSA due to high altitude (conditional recommendation, very low certainty) 1

Oxygen is a reasonable adjunctive therapy, particularly when other options have failed or are contraindicated.

Step 5: Transvenous Phrenic Nerve Stimulation

The AASM suggests phrenic nerve stimulation for:

• Primary CSA
• CSA due to heart failure

This is a conditional recommendation with very low certainty evidence 1. Given the invasive nature, lack of universal accessibility, and high costs, consider other treatments first 1. This represents a newer option recognized in 2025 guidelines but should be reserved for refractory cases in specialized centers.

Common Pitfalls to Avoid

1. Using ASV in HFrEF with LVEF ≤45% without proper risk stratification: Always check ejection fraction before prescribing ASV in heart failure patients. The LVEF <30% group requires extreme caution 1, 2.

2. Failing to optimize underlying conditions first: Treating CSA without addressing heart failure, opioid use, or other precipitants often leads to treatment failure 1.

3. Skipping the CPAP trial: Most guidelines recommend attempting CPAP before ASV, both for cost-effectiveness and because some patients respond adequately 2.

4. Misclassifying mixed sleep apnea: Many patients have both obstructive and central components. Without esophageal pressure monitoring, the true nature may be unclear, affecting treatment choice 1.

5. Ignoring treatment-emergent CSA: This can develop in chronic CPAP users and may signal new atrial fibrillation or heart failure 3.

Quality of Life and Mortality Considerations

CSA is associated with increased mortality and hospitalization in heart failure patients, sleep fragmentation, daytime sleepiness, and poor quality of life 1. Nearly one-fifth of CSA patients die within 5 years of diagnosis in some cohorts 1. Treatment aims to:

• Reduce apnea-hypopnea index
• Improve oxygenation
• Enhance sleep quality and daytime function
• Potentially reduce cardiovascular morbidity and mortality (though hard endpoint data remain limited for most therapies)

The field is shifting from AHI suppression alone to phenotype-guided care prioritizing patient-centered and cardiac outcomes 4, 5.